DRREDDY

The Delhi High Court upheld a ruling allowing

to manufacture and export Semaglutide to countries where Novo Nordisk lacks patent protection. The court refused an interim injunction, enabling international sales for the high-demand GLP-1 drug while litigation remains ongoing.